POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF PD 0348292, AN ORAL, DIRECT FACTOR XA INHIBITOR, IN HEALTHY SUBJECTS.

被引：0
|
作者：
Xuan, D. [1 ]
Boyd, R. [1 ]
DiCarlo, L. [1 ]
机构：
[1] Pfizer Inc, New London, CT USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2010年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S54 / S55
页数：2
相关论文
共 50 条
  • [11] Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects
    Kadokura, Takeshi
    Kashiwa, Makoto
    Groenendaal, Dorien
    Heeringa, Marten
    Mol, Roelof
    Verheggen, Frank
    Garcia-Hernandez, Alberto
    Onkels, Hartmut
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (08) : 431 - 441
  • [12] Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct factor Xa inhibitor in healthy male subjects.
    Kubitza, D
    Becka, M
    Wensing, G
    Voith, B
    Zuehlsdorf, M
    [J]. BLOOD, 2003, 102 (11) : 813A - 813A
  • [13] Pharmacokinetics (PK) and pharmacodynamics (PD) of lanoteplase in healthy subjects.
    Vachharajani, N
    Shyu, W
    Stouffer, B
    Raymond, R
    Liao, W
    Tay, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 180 - 180
  • [14] The pharmacokinetics and pharmacodynamics of TAK-442, an oral, direct factor Xa inhibitor following multiple dosing in healthy male subjects
    Stringer, Fran
    Scott, Graham
    Kupfer, Stuart
    Prescott, Kim
    Jenkins, Robert
    Harding, Sarah
    Cao, Charlie
    Kawamura, Masaki
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 305 - 305
  • [15] Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects
    Kadokura, Takeshi
    Taniuchi, Yuta
    Inoue, Hiroshi
    Saito, Masako
    Iwahana, Mioko
    Yamada, Shunsuke
    Urae, Akinori
    Nakamura, Mashio
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (03) : 200 - 206
  • [16] Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects
    Jiang, Ji
    Hu, Yufang
    Zhang, Jianyan
    Yang, Jueling
    Mueck, Wolfgang
    Kubitza, Dagmar
    Bauer, Richard J.
    Meng, Ling
    Hu, Pei
    [J]. THROMBOSIS AND HAEMOSTASIS, 2010, 103 (01) : 234 - 241
  • [17] Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
    Kubitza, D
    Becka, M
    Wensing, G
    Voith, B
    Zuehlsdorf, M
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (12) : 873 - 880
  • [18] Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects
    Dagmar Kubitza
    Michael Becka
    Georg Wensing
    Barbara Voith
    Michael Zuehlsdorf
    [J]. European Journal of Clinical Pharmacology, 2005, 61 : 873 - 880
  • [19] Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
    Joachim Stangier
    Hildegard Stähle
    Karin Rathgen
    Reinhold Fuhr
    [J]. Clinical Pharmacokinetics, 2008, 47 : 47 - 59
  • [20] Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
    Stangier, Joachim
    Staehle, Hildegard
    Rathgen, Karin
    Fuhr, Reinhold
    [J]. CLINICAL PHARMACOKINETICS, 2008, 47 (01) : 47 - 59
12345